Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
By Dr. Matthew Watson
CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company’s R&D Committee and Nominating and Corporate Governance Committee.
Read this article:
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
Related Post
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally - December 18th, 2024
- Vaccinex Announces Receipt of Delisting Notification from Nasdaq - December 18th, 2024
- Adia Nutrition Unveils Exclusive Artwork by Renowned Performance Artist Rock Demarco at First Clinic - December 18th, 2024
- NYMOX Announces Trading Resumed and New Listing on OTCQB Market - December 18th, 2024
- Bio Usawa Names Former Ghana Food and Drug Authority Director Eric Karikari-Boateng as Head of Global Regulatory Strategy - December 18th, 2024
- AB Science provides a summary of the webcast held on December 16, 2024 - December 18th, 2024
- Ultimovacs ASA – Mandatory notification of trade - December 18th, 2024
- Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare... - December 18th, 2024
- Key information relating to the potential subsequent repair offering to be carried out by Ultimovacs ASA - December 18th, 2024
- Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18,... - December 18th, 2024
- Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity - December 18th, 2024
- Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - December 18th, 2024
- electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic... - December 18th, 2024
- Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - December 18th, 2024
- NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - December 18th, 2024
- AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - December 18th, 2024
- Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - December 18th, 2024
- NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology - December 18th, 2024
- Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution - December 18th, 2024
- Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - December 9th, 2024
- Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s... - December 9th, 2024
- Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - December 9th, 2024
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory... - December 9th, 2024
- Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on... - December 9th, 2024
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With... - December 9th, 2024
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with... - December 9th, 2024
- Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin... - December 9th, 2024
- Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic... - December 9th, 2024
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become... - December 9th, 2024
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 9th, 2024
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 9th, 2024
- Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th... - December 9th, 2024
- Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - December 9th, 2024
- Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’ - December 9th, 2024
- Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function - December 9th, 2024
- AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related... - December 9th, 2024
- Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders - December 9th, 2024
- Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives - November 29th, 2024
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - November 29th, 2024
- Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
- Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel - November 29th, 2024
- Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
- PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area - November 29th, 2024
- SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - November 29th, 2024
- Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - November 29th, 2024
- Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - November 29th, 2024
- Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - November 29th, 2024
- Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - November 29th, 2024
- QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis - November 29th, 2024
- Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq - November 29th, 2024
- Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia - November 29th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notification - November 29th, 2024
- HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms - November 29th, 2024
- Kane Biotech Announces Third Quarter 2024 Financial Results - November 29th, 2024
- Rakovina Therapeutics Announces Private Placement Offering - November 29th, 2024
- MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS) - November 29th, 2024
- Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - November 29th, 2024
- Panbela Provides Business Update and Reports Q3 2024 Financial Results - November 15th, 2024
- Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability - November 15th, 2024
- Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
- TFF Pharmaceuticals Announces It Will Wind Down Operations - November 15th, 2024
- Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - November 15th, 2024
- GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for... - November 15th, 2024
- Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - November 15th, 2024
- HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights - November 15th, 2024
- Lowell Farms Inc. Announces Unaudited Third Quarter 2024 Financial and Operational Results - November 15th, 2024
- Osteal Therapeutics Announces Positive 12-Month Results from the APEX Clinical Trial Program at the 2024 American Association of Hip and Knee Surgeons... - November 15th, 2024
- UPDATE - Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials - November 15th, 2024
- Avicanna Reports Q3 2024 - November 15th, 2024
- Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - November 15th, 2024
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in... - November 15th, 2024
- Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - November 15th, 2024
- Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) - November 15th, 2024
- Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio - November 15th, 2024
- Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - November 15th, 2024
- NINER Pharmaceutical Strengthens Global Presence with Strategic IV Fluid Supply Initiative for the U.S. and Latin American Markets - November 15th, 2024
- Bavarian Nordic Announces Interim Results for the First Nine Months of 2024 - November 15th, 2024
Global News Feed
Comments Off on Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors |
August 18th, 2022
This author published 5912 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research